

ATAGI recommendation for using 1 dose of 9vHPV vaccine in immunocompetent females and males aged ≥ 9 years

One dose of 9vHPV vaccine is recommended for routine immunisation in immunocompetent males and females aged 9 to 26 years. The optimal age for HPV vaccination is around 12 to 13 years prior to HPV exposure.

Justification

There is a large body of evidence to support the efficacy and effectiveness of one dose of HPV vaccine in immunocompetent adolescents and young adults. This GRADE assessment is supported by the findings of the WHO SAGE systematic review.^{1,2}

References

1. Cochrane Response. Efficacy, effectiveness and immunogenicity of one dose of HPV vaccine compared with no vaccination, two doses, or three doses World Health Organization; March 2022. Available from: [https://cdn-auth-cms.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-\(hpv\)/systematic-review-of-1-dose-of-hpv-vaccinec14d7ee3-e409-4a1a-afd9-c3e7e0dd2bd9.pdf](https://cdn-auth-cms.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-(hpv)/systematic-review-of-1-dose-of-hpv-vaccinec14d7ee3-e409-4a1a-afd9-c3e7e0dd2bd9.pdf) (Accessed 24 April 2023).
2. Strategic Advisory Group of Experts (SAGE). Strategic Advisory Group of Experts (SAGE) Working Group on potential contribution of HPV vaccines and immunization towards cervical cancer elimination. SAGE meeting April 2022; March 2022. Available from: chrome-extension://efaidnbmnnnibpcajpcgclefindmkaj/[https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-\(hpv\)/hpv-background-document--report-march-2022.pdf?sfvrsn=b600e252_1](https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/human-papillomavirus-(hpv)/hpv-background-document--report-march-2022.pdf?sfvrsn=b600e252_1)